We are live on ! Find out more
IRD

Opus Genetics
IRD

33 hedge funds and large institutions have $6.23M invested in Opus Genetics in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less funds holding

Funds holding: 35 → 33 (-2)

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

38% less capital invested

Capital invested by funds: $10.1M → $6.23M (-$3.85M)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
33
Holders Change
-2
Holders Change %
-5.71%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
6
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
+$2.31M
2
Renaissance Technologies
Renaissance Technologies
New York
+$213K
3
SM
Sabby Management
Florida
+$99.1K
4
TSS
Two Sigma Securities
New York
+$46.6K
5
TRCT
Tower Research Capital (TRC)
New York
+$8.7K

Top Sellers

Rank Fund Capital Flow
1
CL
CSS LLC
Illinois
-$5.21M
2
Citadel Advisors
Citadel Advisors
Florida
-$33K
3
VKH
Virtu KCG Holdings
New York
-$17.5K
4
AT
Arden Trust
Delaware
-$13K
5
UBS Group
UBS Group
Switzerland
-$11.8K

IRD Hedge Fund Activity: Q3 2016 in Review

33 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q3 2016, worth a combined $6.23M — down 38% from $10.1M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of IRD and 2 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 6 added.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $2.31M. The largest seller was CSS LLC, exiting entirely with an estimated $5.21M sold.

  • 33 institutional investors held Opus Genetics (IRD) as of Q3 2016, down from 35 in Q2 2016.
  • Funds reported $6.23M of Opus Genetics stock for Q3 2016, down 38% quarter-over-quarter.
  • 2 funds opened new Opus Genetics positions in Q3 2016 and 4 closed out, a net change of -2 holders.
  • The largest Opus Genetics buyer in Q3 2016 was Anson Funds Management, an estimated $2.31M added.
  • The largest Opus Genetics seller in Q3 2016 was CSS LLC, an estimated $5.21M sold.

Based on aggregated 13F filings for Q3 2016.